GC Genome KRX:340450KOSDAQ
지씨지놈 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, GC Genome reported revenue of ₩8.3bn, up 6.2% year on year, and operating profit of ₩433m. GC Genome (지씨지놈) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
GC Genome quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩8.3bn | +6.2% | ₩433m margin 5.2% | ₩781m |
| Q1 2026 | ₩7.4bn | +9.1% | ₩140m margin 1.9% | ₩814m |
| Q4 2025 derived | ₩8.1bn | +10.2% | ₩201m margin 2.5% | ₩2.4bn |
| Q3 2025 | ₩8.8bn | +30.9% | ₩773m margin 8.7% | ₩1.4bn |
| Q2 2025 | ₩7.8bn | +29.0% | ₩287m margin 3.7% | −₩73m |
| Q1 2025 | ₩6.8bn | – | −₩25m margin −0.4% | ₩297m |
| Q4 2024 derived | ₩7.3bn | – | ₩98m margin 1.3% | ₩783m |
| Q3 2024 | ₩6.8bn | – | −₩17m margin −0.2% | −₩994m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GC Genome top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.